Vistagen (VTGN) announced that the last patient has completed the randomized, double-blind, placebo-controlled portion of the PALISADE-3 Phase 3 clinical trial evaluating fasedienol for the acute treatment of social anxiety disorder. The open label extension of the study is currently ongoing.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTGN:
- Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks
- VistaGen Therapeutics Appoints Paul R. Edick to Board
- Vistagen’s Phase 3 Trial: A Potential Game-Changer for Anxiety Treatment?
- Vistagen’s Phase 3 Trial of Fasedienol Nasal Spray: A Potential Game-Changer for Anxiety Treatment
- Vistagen’s Promising Phase 2 Trial for Anxiety Treatment: A Market Game Changer?